Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Substance Profile
Esketamine is the S-enantiomer of ketamine, approved by the FDA in 2019 as a nasal spray (Spravato) for treatment-resistant depression. It shows approximately twice the affinity at the NMDA receptor compared to racemic ketamine and is administered in clinical settings under supervision.
NEGATIVE ALLOSTERIC MODULATOR
No subjective effects data available yet.
No linked studies yet.